SEC Form 6-K filed by Legend Biotech Corporation
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
Date of Report: November 5, 2024
Commission File Number: 001-39307
Legend Biotech Corporation
(Translation of registrant's name into English)
2101 Cottontail Lane
Somerset, New Jersey 08873
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ] Form 40-F [ ]
Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple Myeloma
On November 5, 2024, Legend Biotech Corporation (“Legend Biotech”) issued a press release announcing that new data will be presented on minimal residual disease (MRD) negativity rates from the Phase 3 CARTITUDE-4 trial in multiple myeloma patients treated with CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) versus standard of care (SoC). The study evaluated lenalidomide-refractory patients who have received one to three prior lines of therapy and will be featured in an oral presentation on Monday, December 9, 2024, at 5:45 p.m. PT at the 66th Annual American Society of Hematology (ASH) Annual Meeting in San Diego. The press release is attached to this Form 6-K as Exhibit 99.1.
This report on Form 6-K, including Exhibit 99.1 (other than the information included under “About Legend Biotech”), is hereby incorporated herein by reference in the registration statements of Legend Biotech on Form F-3 (Nos. 333-278050, 333-257625, and 333-272222) and Form S-8 (No. 333-239478), to the extent not superseded by documents or reports subsequently filed.
EXHIBIT INDEX
Exhibit | Title | |
99.1 | Press Release, dated November 5, 2024 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Legend Biotech Corporation | ||
(Registrant) | ||
Date: November 4, 2024 | /s/ Ying Huang | |
Ying Huang, Ph.D. | ||
Chief Executive Officer | ||